Arrowhead Pharmaceuticals Stock Rises on Late-Stage Trial Success
Arrowhead Pharmaceuticals (ARWR) stock surged over 20%, reaching a new 52-week high, following the announcement of successful late-stage trial results for its lipid-lowering agent. The positive outcome was highlighted by Cantor Fitzgerald as 'a meaningful derisking event,' signaling potential progress in the company's drug development pipeline.
Tickers: $ARWR